Diabetes News
Most Popular Diabetes Story
FDA nod fuels Bydureon vs. Victoza bout
Amylin Pharmaceuticals' ($AMLN) projected blockbuster Bydureon has won FDA approval, adding muscle to the San Diego-based drug company's counterpunch against rival Novo Nordisk ($NVO) in the big Read more...
Latest Headlines
- February 2, 2012
- February 2, 2012
- January 30, 2012
- January 24, 2012
- January 18, 2012
- January 17, 2012
- December 7, 2011
- November 9, 2011
- October 7, 2011
- September 23, 2011
- September 22, 2011
- September 13, 2011
- August 26, 2011
- July 22, 2011
- June 27, 2011
- June 22, 2011
- June 9, 2011
- June 9, 2011
- June 1, 2011
- April 25, 2011
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
